Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, Canadian, Non-interventional, Cohort Study of the Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adult Patients Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)

Next Previous
Search
Trial Profile

Multi-center, Canadian, Non-interventional, Cohort Study of the Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adult Patients Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms BIC-STaR; BICSTaR
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 07 Nov 2024 According to a Gilead Sciences media release, four-year outcomes data from this study will be presented at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November 10-13.
    • 25 Jul 2024 According to a Gilead Sciences media release, data from the study were presented at the 25th International AIDS Conference (AIDS 2024).
    • 25 Jul 2024 Results presented in the Gilead Sciences Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top